Biotechnology company
Appears in 1 story · Last updated Nov 1, 2026
Completed dosing in confirmatory RGX-202 study; BLA planned for Q3 2026
Regenxbio's RGX-202 met the main goal of its AFFINITY DUCHENNE trial in May 2026. In 93% of treated boys with usable biopsies, muscle made microdystrophin, a shortened form of the missing protein, at more than 10% of normal levels by week 12. The company finished dosing a confirmatory study and plans to file for FDA approval in the third quarter of 2026.
Updated Nov 1
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
